{"id":10991,"date":"2010-10-07T11:44:19","date_gmt":"2010-10-07T15:44:19","guid":{"rendered":"http:\/\/asweetlife.org\/?p=10991"},"modified":"2015-12-30T02:43:42","modified_gmt":"2015-12-30T07:43:42","slug":"spherix-inc-announces-good-results-for-new-type-2-diabetes-drug","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=10991","title":{"rendered":"Spherix Inc. Announces Good Results for New Type 2 Diabetes Drug"},"content":{"rendered":"

\"\"<\/a>Spherix Inc., a biotechnology company based in Maryland, announced results of its NEET Phase 3 study of D-tagatose as a monotherapy for type 2 diabetes.
The NEET (Naturlose\u00ae Efficacy Evaluation Trial) data showed a significant drop in Hemoglobin A1c (HbA1c) levels among patients treated with D-tagatose.<\/p>\n

Patients in the study had a low average randomization HbA1c of 7.5% globally. An HbA1c level of 6% or below is considered normal. An 8% level is considered high. The American Diabetes Association recommends a goal of reducing HbA1c to 7% or below in people with diabetes.<\/p>\n

For the full press release click here.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Spherix Inc., a biotechnology company based in Maryland, announced results of its NEET Phase 3 study of D-tagatose as a monotherapy for type 2 diabetes.
\nThe NEET (Naturlose\u00ae Efficacy Evaluation Trial) data showed a significant drop in Hemoglobin A1c (HbA1c) levels among patients treated with D-tagatose….<\/p>\n","protected":false},"author":131,"featured_media":10993,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1445],"tags":[],"yoast_head":"\nSpherix Inc. Announces Good Results for New Type 2 Diabetes Drug<\/title>\n<meta name=\"description\" content=\"Spherix Inc., a biotechnology company based in Maryland, announced results of its NEET Phase 3 study of D-tagatose as a monotherapy for type 2 diabetes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=10991\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ASweetLife Team\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=10991\",\"url\":\"https:\/\/asweetlife.org\/?p=10991\",\"name\":\"Spherix Inc. Announces Good Results for New Type 2 Diabetes Drug\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=10991#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=10991#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/10\/Spherix-Logo.jpg\",\"datePublished\":\"2010-10-07T15:44:19+00:00\",\"dateModified\":\"2015-12-30T07:43:42+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\"},\"description\":\"Spherix Inc., a biotechnology company based in Maryland, announced results of its NEET Phase 3 study of D-tagatose as a monotherapy for type 2 diabetes.\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=10991#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=10991\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=10991#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/10\/Spherix-Logo.jpg\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/10\/Spherix-Logo.jpg\",\"width\":285,\"height\":102,\"caption\":\"Spherix Logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=10991#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Spherix Inc. Announces Good Results for New Type 2 Diabetes Drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\",\"name\":\"ASweetLife Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"caption\":\"ASweetLife Team\"},\"url\":\"https:\/\/asweetlife.org\/?author=131\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Spherix Inc. Announces Good Results for New Type 2 Diabetes Drug","description":"Spherix Inc., a biotechnology company based in Maryland, announced results of its NEET Phase 3 study of D-tagatose as a monotherapy for type 2 diabetes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=10991","twitter_misc":{"Written by":"ASweetLife Team"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=10991","url":"https:\/\/asweetlife.org\/?p=10991","name":"Spherix Inc. Announces Good Results for New Type 2 Diabetes Drug","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=10991#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=10991#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/10\/Spherix-Logo.jpg","datePublished":"2010-10-07T15:44:19+00:00","dateModified":"2015-12-30T07:43:42+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585"},"description":"Spherix Inc., a biotechnology company based in Maryland, announced results of its NEET Phase 3 study of D-tagatose as a monotherapy for type 2 diabetes.","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=10991#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=10991"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=10991#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/10\/Spherix-Logo.jpg","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/10\/Spherix-Logo.jpg","width":285,"height":102,"caption":"Spherix Logo"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=10991#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"Spherix Inc. Announces Good Results for New Type 2 Diabetes Drug"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585","name":"ASweetLife Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","caption":"ASweetLife Team"},"url":"https:\/\/asweetlife.org\/?author=131"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/10991"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10991"}],"version-history":[{"count":0,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/10991\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/10993"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10991"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10991"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10991"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}